WuXi STA Adds New Peptide Manufacturing Capacity and Large-Scale Continuous Purification System

WuXi STA Adds New Peptide Manufacturing Capacity and Large-Scale Continuous Purification System

Expansion Enhances WuXi TIDES CRDMO Platform Capability and Capacity for Global Partners

Shanghai, China, April 5, 2023: WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), announces that it has added two 2,000 L reactors and a large-scale continuous purification system for peptide manufacturing at its Changzhou campus.

The new additions further enhance the capability and capacity of WuXi TIDES. As an integral part of WuXi STA, WuXi TIDES is an end-to-end CRDMO platform for oligonucleotide, peptide, and related synthetic conjugates (“TIDES” drugs), simplifying TIDES drug development by providing all discovery, CMC development, and the manufacturing supply chain under one roof.

With the two new 2,000 L reactors in operation, the total reactor volume of the Solid Phase Peptide Synthesizers (SPPS) at WuXi TIDES has increased to over 10,000 L.

In addition to the peptide capacity expansion, WuXi TIDES also added a new continuous purification system that features 300-DAC twin columns for continuous purification of kilogram-scale peptide and oligonucleotide. The continuous mode enables a purification process with a faster turnaround time and lower solvent consumption, allowing for a more efficient and sustainable peptide and oligonucleotide manufacturing.

Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, said, "We are pleased to support our global partners in their efforts to develop TIDES therapies for patients in need. We are committed to continuously enhancing our WuXi TIDES CRDMO platform's capacity and capability to expedite the development and commercialization of more innovative therapies for patients worldwide."